Brendan Michael McCarthy

Michael Kim

Aashi Shah

- Beneficient was notified by Nasdaq on **October 29, 2025**, that it had regained compliance with the **periodic reporting requirement** and the **minimum $35 million market value of listed securities requirement**.  **[1775734_0001493152-25-020271_ex99-1.htm:0]** 
- This compliance was achieved by filing its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.  **[1775734_0001493152-25-020271_ex99-1.htm:0]** 
- The company **remains noncompliant** with the **$1.00 per share bid price requirement**.  **[1775734_0001493152-25-020271_ex99-1.htm:0]** **[1775734_0001493152-25-020271_form8-k.htm:2]** 
- To address the bid price requirement, Beneficient plans to seek stockholder approval for a **reverse stock split** of its common stock.  **[1775734_0001493152-25-020271_ex99-1.htm:0]** **[1775734_0001493152-25-020271_form8-k.htm:2]**

Beneficient Regains Compliance with Nasdaq Periodic Filing and Market Value Requirements

- Beneficient's Chairman, Thomas O. Hicks, and Interim CEO, James G. Silk, converted a combined **$52.6 million** of Preferred A-1 Unit Accounts from a subsidiary into **101,294,288 shares** of Class A common stock on October 15, 2025.  **[1775734_0001493152-25-018825_form8-k.htm:0]** **[1775734_0001493152-25-018825_ex99-1.htm:0]** 
- This conversion increased the total Class A Common Stock outstanding to **110,758,536 shares** immediately after the transaction.  **[1775734_0001493152-25-018825_form8-k.htm:0]** 
- The company stated the conversion aims to simplify its capital structure and align leadership interests with stockholders, especially as Beneficient addresses its non-compliance with Nasdaq's minimum stockholders' equity requirement.  **[1775734_0001493152-25-018825_ex99-1.htm:0]** 
- The newly issued shares are subject to a lock-up agreement until **October 1, 2028**, during which period the executives will forfeit any appreciation in the shares' value.  **[1775734_0001493152-25-018825_ex99-1.htm:0]** **[1775734_0001493152-25-018825_form8-k.htm:1]**

Beneficient Chairman and Interim CEO Convert Subsidiary Securities to Class A Common Stock

- Beneficient reported a **GAAP revenue of $(12.6) million** and a **GAAP operating loss of $(92.6) million** for the fiscal first quarter ended June 30, 2025, resulting in **basic Class A EPS of $(7.19)**.  **[1775734_0001775734-25-000040_q126earningsrelease.htm:3]** **[1775734_0001775734-25-000040_q126earningsrelease.htm:8]** 
- Operating expenses, excluding non-cash goodwill impairment and loss contingency accrual/release, **declined 1% to $17.2 million** in the fiscal first quarter of 2026 compared to the same period in fiscal 2025.  **[1775734_0001775734-25-000040_q126earningsrelease.htm:0]** 
- The company completed **asset sales generating $38.1 million** in gross proceeds, which were utilized for debt reduction and working capital.  **[1775734_0001775734-25-000040_q126earningsrelease.htm:0]** 
- As of June 30, 2025, Beneficient held **$7.6 million in cash and cash equivalents** and had **total debt of $108.4 million**.  **[1775734_0001775734-25-000040_q126earningsrelease.htm:3]** **[1775734_0001775734-25-000040_q126earningsrelease.htm:9]** 
- On October 15, 2025, Board Chairman Thomas Hicks and interim CEO James Silk converted **$52.6 million** of personally held BCH Preferred Series A-1 holdings into Class A common stock as part of plans to regain Nasdaq compliance.  **[1775734_0001775734-25-000040_q126earningsrelease.htm:0]**

Beneficient Reports Fiscal First Quarter 2026 Results

- Beneficient reported a **net income attributable to common shareholders of $51.162 million** for the fiscal year ended March 31, 2025, with **Class A diluted EPS of $0.06**.  **[1775734_0001775734-25-000020_q425earningsrelease.htm:9]** 
- The company's **GAAP operating loss for FY 2025 was $(24.185) million**, a significant improvement from **$(2,648.546) million** in FY 2024, primarily due to lower non-cash goodwill impairment.  **[1775734_0001775734-25-000020_q425earningsrelease.htm:4]** **[1775734_0001775734-25-000020_q425earningsrelease.htm:9]** 
- As of March 31, 2025, Beneficient had **$1.3 million in cash and cash equivalents** and **$117.9 million in debt**.  **[1775734_0001775734-25-000020_q425earningsrelease.htm:4]** **[1775734_0001775734-25-000020_q425earningsrelease.htm:10]** 
- Management stated that fiscal 2025 was a "turning point," marked by **streamlined operations, resolved legal issues, and a completed executive transition**, positioning the company to expand its Preferred Liquidity Provider and Primary Commitment programs.  **[1775734_0001775734-25-000020_q425earningsrelease.htm:0]**

Beneficient Reports Fiscal Year Ended March 31, 2025 Results

- On **September 9, 2025**, Beneficient was granted an extension by The Nasdaq Stock Market LLC to maintain its listing.  **[1775734_0001493152-25-013630_ex99-1.htm:0]** 
- The extension is conditional on the company filing its Annual Report on Form 10-K for the fiscal year ended **March 31, 2025**, and its Quarterly Report on Form 10-Q for the quarter ended **June 30, 2025**, and demonstrating compliance with the **$1.00 per share bid price requirement**.  **[1775734_0001493152-25-013630_ex99-1.htm:0]** 
- Beneficient plans to seek stockholder approval for a **reverse stock split** of its common stock to meet the bid price requirement if it has not regained compliance within the extension period.  **[1775734_0001493152-25-013630_ex99-1.htm:0]** **[1775734_0001493152-25-013630_form8-k.htm:2]**

Beneficient (BENF)